poisar

Stocks · News reference

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Jul 23, 2026, 4:12 PMBenzinga Newsdesk

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

KNSA
Source
benzinga
Observed
Jul 23, 2026, 4:12 PM
Checked
Jul 23, 2026, 4:12 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading